You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDexfenfluramine
Accession NumberDB01191  (APRD00648)
TypeSmall Molecule
GroupsApproved, Illicit, Withdrawn
DescriptionDexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. It was for some years in the mid-1990s approved by the United States Food and Drug Administration for the purposes of weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn.
Structure
Thumb
Synonyms
(+)-fenfluramine
(S)-fenfluramine
(S)-N-Ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine
D-N-Ethyl-alpha-methyl-m-trifluoromethylphenethylamine
Dexfenfluramina
Dexfenfluramine
Dexfenfluraminum
Dextrofenfluramine
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AdifaxNot Available
ReduxNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIE35R3G56OV
CAS number3239-44-9
WeightAverage: 231.2573
Monoisotopic: 231.123484132
Chemical FormulaC12H16F3N
InChI KeyInChIKey=DBGIVFWFUFKIQN-VIFPVBQESA-N
InChI
InChI=1S/C12H16F3N/c1-3-16-9(2)7-10-5-4-6-11(8-10)12(13,14)15/h4-6,8-9,16H,3,7H2,1-2H3/t9-/m0/s1
IUPAC Name
ethyl[(2S)-1-[3-(trifluoromethyl)phenyl]propan-2-yl]amine
SMILES
CCN[C@@H](C)CC1=CC=CC(=C1)C(F)(F)F
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenethylamines
Direct ParentAmphetamines and derivatives
Alternative Parents
Substituents
  • Amphetamine or derivatives
  • Phenylpropane
  • Aralkylamine
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the management of obesity including weight loss and maintenance of weight loss in patients on a reduced calorie diet
PharmacodynamicsUsed to treat diabetes and obesity, Dexfenfluramine decreases caloric intake by increasing serotonin levels in the brain’s synapses. Dexfenfluramine acts as a serotonin reuptake inhibitor. It also causes release of serotonin from the synaptosomes.
Mechanism of actionDexfenfluramine binds to the serotonin reuptake pump. This causes inhbition of serotonin reuptake. The increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates.
Related Articles
AbsorptionWell-absorbed from the gastrointestinal tract.
Volume of distributionNot Available
Protein binding36%
MetabolismNot Available
Route of eliminationNot Available
Half life17-20 hours
ClearanceNot Available
ToxicitySymptoms of overdose include respiratory failure and cardiac arrest leading to death.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9868
Caco-2 permeable+0.7004
P-glycoprotein substrateNon-substrate0.5138
P-glycoprotein inhibitor INon-inhibitor0.5934
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.7404
CYP450 2C9 substrateNon-substrate0.8506
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.6781
CYP450 1A2 substrateInhibitor0.8859
CYP450 2C9 inhibitorNon-inhibitor0.8616
CYP450 2D6 inhibitorInhibitor0.7253
CYP450 2C19 inhibitorNon-inhibitor0.5205
CYP450 3A4 inhibitorNon-inhibitor0.5219
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6657
Ames testNon AMES toxic0.8808
CarcinogenicityNon-carcinogens0.6397
BiodegradationNot ready biodegradable0.984
Rat acute toxicity3.1255 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9666
hERG inhibition (predictor II)Inhibitor0.7811
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP3.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0215 mg/mLALOGPS
logP3.3ALOGPS
logP3.47ChemAxon
logS-4ALOGPS
pKa (Strongest Basic)10.22ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area12.03 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity59.2 m3·mol-1ChemAxon
Polarizability22.69 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesA08AA04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (49.1 KB)
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Dexfenfluramine can be increased when it is combined with Abiraterone.
AmiodaroneThe metabolism of Dexfenfluramine can be decreased when combined with Amiodarone.
ArtemetherThe metabolism of Dexfenfluramine can be decreased when combined with Artemether.
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Dexfenfluramine resulting in a loss in efficacy.
AtomoxetineThe metabolism of Dexfenfluramine can be decreased when combined with Atomoxetine.
AzithromycinThe metabolism of Dexfenfluramine can be decreased when combined with Azithromycin.
BetaxololThe metabolism of Dexfenfluramine can be decreased when combined with Betaxolol.
BortezomibThe metabolism of Dexfenfluramine can be decreased when combined with Bortezomib.
BupropionThe metabolism of Dexfenfluramine can be decreased when combined with Bupropion.
CaffeineThe metabolism of Dexfenfluramine can be decreased when combined with Caffeine.
CarbamazepineThe metabolism of Dexfenfluramine can be increased when combined with Carbamazepine.
CelecoxibThe metabolism of Dexfenfluramine can be decreased when combined with Celecoxib.
ChloroquineThe metabolism of Dexfenfluramine can be decreased when combined with Chloroquine.
ChlorpromazineThe metabolism of Dexfenfluramine can be decreased when combined with Chlorpromazine.
CholecalciferolThe metabolism of Dexfenfluramine can be decreased when combined with Cholecalciferol.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Dexfenfluramine.
CimetidineThe metabolism of Dexfenfluramine can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Dexfenfluramine can be decreased when combined with Cinacalcet.
CitalopramThe metabolism of Dexfenfluramine can be decreased when combined with Citalopram.
ClemastineThe metabolism of Dexfenfluramine can be decreased when combined with Clemastine.
ClobazamThe metabolism of Dexfenfluramine can be decreased when combined with Clobazam.
ClomipramineThe metabolism of Dexfenfluramine can be decreased when combined with Clomipramine.
ClotrimazoleThe metabolism of Dexfenfluramine can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Dexfenfluramine can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Dexfenfluramine can be increased when it is combined with Cobicistat.
CocaineThe metabolism of Dexfenfluramine can be decreased when combined with Cocaine.
Cyproterone acetateThe serum concentration of Dexfenfluramine can be decreased when it is combined with Cyproterone acetate.
DarifenacinThe metabolism of Dexfenfluramine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Dexfenfluramine can be increased when it is combined with Darunavir.
DeferasiroxThe serum concentration of Dexfenfluramine can be increased when it is combined with Deferasirox.
DelavirdineThe metabolism of Dexfenfluramine can be decreased when combined with Delavirdine.
DesipramineThe metabolism of Dexfenfluramine can be decreased when combined with Desipramine.
DiphenhydramineThe metabolism of Dexfenfluramine can be decreased when combined with Diphenhydramine.
DronedaroneThe metabolism of Dexfenfluramine can be decreased when combined with Dronedarone.
DuloxetineThe metabolism of Dexfenfluramine can be decreased when combined with Duloxetine.
EliglustatThe metabolism of Dexfenfluramine can be decreased when combined with Eliglustat.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dexfenfluramine.
FluoxetineThe metabolism of Dexfenfluramine can be decreased when combined with Fluoxetine.
FluvoxamineThe metabolism of Dexfenfluramine can be decreased when combined with Fluvoxamine.
HaloperidolThe metabolism of Dexfenfluramine can be decreased when combined with Haloperidol.
ImipramineThe metabolism of Dexfenfluramine can be decreased when combined with Imipramine.
IndinavirThe metabolism of Dexfenfluramine can be decreased when combined with Indinavir.
IsoniazidThe metabolism of Dexfenfluramine can be decreased when combined with Isoniazid.
KetoconazoleThe metabolism of Dexfenfluramine can be decreased when combined with Ketoconazole.
LidocaineThe metabolism of Dexfenfluramine can be decreased when combined with Lidocaine.
LopinavirThe metabolism of Dexfenfluramine can be decreased when combined with Lopinavir.
LorcaserinThe metabolism of Dexfenfluramine can be decreased when combined with Lorcaserin.
LumefantrineThe metabolism of Dexfenfluramine can be decreased when combined with Lumefantrine.
MethadoneThe metabolism of Dexfenfluramine can be decreased when combined with Methadone.
MethotrimeprazineThe metabolism of Dexfenfluramine can be decreased when combined with Methotrimeprazine.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Dexfenfluramine.
MetoprololThe metabolism of Dexfenfluramine can be decreased when combined with Metoprolol.
MexiletineThe metabolism of Dexfenfluramine can be decreased when combined with Mexiletine.
MirabegronThe metabolism of Dexfenfluramine can be decreased when combined with Mirabegron.
NevirapineThe metabolism of Dexfenfluramine can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Dexfenfluramine can be decreased when combined with Nicardipine.
NilotinibThe metabolism of Dexfenfluramine can be decreased when combined with Nilotinib.
OsimertinibThe serum concentration of Dexfenfluramine can be decreased when it is combined with Osimertinib.
PanobinostatThe metabolism of Dexfenfluramine can be decreased when combined with Panobinostat.
ParoxetineThe metabolism of Dexfenfluramine can be decreased when combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Dexfenfluramine can be decreased when it is combined with Peginterferon alfa-2b.
PhenobarbitalThe metabolism of Dexfenfluramine can be increased when combined with Phenobarbital.
PrimidoneThe metabolism of Dexfenfluramine can be increased when combined with Primidone.
PromazineThe metabolism of Dexfenfluramine can be decreased when combined with Promazine.
QuinidineThe metabolism of Dexfenfluramine can be decreased when combined with Quinidine.
QuinineThe metabolism of Dexfenfluramine can be decreased when combined with Quinine.
RanolazineThe metabolism of Dexfenfluramine can be decreased when combined with Ranolazine.
RifampicinThe metabolism of Dexfenfluramine can be increased when combined with Rifampicin.
RitonavirThe metabolism of Dexfenfluramine can be decreased when combined with Ritonavir.
RolapitantThe metabolism of Dexfenfluramine can be decreased when combined with Rolapitant.
RopiniroleThe metabolism of Dexfenfluramine can be decreased when combined with Ropinirole.
SertralineThe metabolism of Dexfenfluramine can be decreased when combined with Sertraline.
SimeprevirThe metabolism of Dexfenfluramine can be decreased when combined with Simeprevir.
StiripentolThe metabolism of Dexfenfluramine can be decreased when combined with Stiripentol.
TenofovirThe metabolism of Dexfenfluramine can be decreased when combined with Tenofovir.
TerbinafineThe metabolism of Dexfenfluramine can be decreased when combined with Terbinafine.
TeriflunomideThe serum concentration of Dexfenfluramine can be decreased when it is combined with Teriflunomide.
TheophyllineThe metabolism of Dexfenfluramine can be decreased when combined with Theophylline.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Dexfenfluramine.
ThioridazineThe metabolism of Dexfenfluramine can be decreased when combined with Thioridazine.
TiclopidineThe metabolism of Dexfenfluramine can be decreased when combined with Ticlopidine.
TipranavirThe metabolism of Dexfenfluramine can be decreased when combined with Tipranavir.
TranylcypromineThe metabolism of Dexfenfluramine can be decreased when combined with Tranylcypromine.
VemurafenibThe serum concentration of Dexfenfluramine can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Dexfenfluramine can be decreased when combined with Venlafaxine.
ZiprasidoneThe metabolism of Dexfenfluramine can be decreased when combined with Ziprasidone.
Food Interactions
  • Take with meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Eddahibi S, Adnot S, Frisdal E, Levame M, Hamon M, Raffestin B: Dexfenfluramine-associated changes in 5-hydroxytryptamine transporter expression and development of hypoxic pulmonary hypertension in rats. J Pharmacol Exp Ther. 2001 Apr;297(1):148-54. [PubMed:11259539 ]
  2. Russell BR, Laverty R: The effect of (R)-HA966 or ACEA 1021 on dexfenfluramine or (S)-MDMA-induced changes in temperature, activity, and neurotoxicity. Pharmacol Biochem Behav. 2001 Mar;68(3):565-74. [PubMed:11325413 ]
  3. Rothman RB, Jayanthi S, Wang X, Dersch CM, Cadet JL, Prisinzano T, Rice KC, Baumann MH: High-dose fenfluramine administration decreases serotonin transporter binding, but not serotonin transporter protein levels, in rat forebrain. Synapse. 2003 Dec 1;50(3):233-9. [PubMed:14515341 ]
  4. Johnson GJ, Leis LA, Dunlop PC, Weir EK: The effect of the anorectic agent, d-fenfluramine, and its primary metabolite, d-norfenfluramine, on intact human platelet serotonin uptake and efflux. J Thromb Haemost. 2003 Dec;1(12):2663-8. [PubMed:14675103 ]
  5. Wang X, Baumann MH, Xu H, Rothman RB: 3,4-methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein. Synapse. 2004 Sep 15;53(4):240-8. [PubMed:15266556 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Vickers SP, Clifton PG, Dourish CT, Tecott LH: Reduced satiating effect of d-fenfluramine in serotonin 5-HT(2C) receptor mutant mice. Psychopharmacology (Berl). 1999 Apr;143(3):309-14. [PubMed:10353435 ]
  2. Wilson AW, Costall B, Neill JC: Manipulation of operant responding for an ethanol-paired conditioned stimulus in the rat by pharmacological alteration of the serotonergic system. J Psychopharmacol. 2000;14(4):340-6. [PubMed:11198050 ]
  3. Vickers SP, Dourish CT, Kennett GA: Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors. Neuropharmacology. 2001 Aug;41(2):200-9. [PubMed:11489456 ]
  4. Tomkins DM, Joharchi N, Tampakeras M, Martin JR, Wichmann J, Higgins GA: An investigation of the role of 5-HT(2C) receptors in modifying ethanol self-administration behaviour. Pharmacol Biochem Behav. 2002 Apr;71(4):735-44. [PubMed:11888565 ]
  5. Bickerdike MJ: 5-HT2C receptor agonists as potential drugs for the treatment of obesity. Curr Top Med Chem. 2003;3(8):885-97. [PubMed:12678838 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23